research Symptom Experience of Lung Cancer Patients Treated With Immunotherapy Combined with Chemotherapy: A Longitudinal Study
Lung cancer patients on immunotherapy and chemotherapy often experience severe fatigue, drowsiness, and appetite loss.
Search
for
Sort by
Research
480-510 / 1000+ results 
research Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients
Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
research 1379 Cyclosporin A suppresses TGF-β2 expression via calcineurin/NFAT pathway in human dermal papilla cells
Cyclosporin A, a drug, reduces TGF-β2 expression in skin cells, potentially causing excessive hair growth through a process involving the calcineurin/NFAT pathway.
research Allergen desensitization reduces the severity of relapsed alopecia areata in dust‐mite allergic patients
Allergen desensitization reduces hair loss severity in dust-mite allergic alopecia areata patients.
research Biochemical properties of red tilapia (Oreochromis niloticus) protein hydrolysates.
Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
research Predominance of CD27-PD-1- Effector Memory T Cells Re-Expressing CD45RA Characterizes Treatment-Resistant Severe Alopecia Areata
CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.
research Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research Post-COVID-19 Alopecia Universalis: Autoimmune Hair Loss and the Challenge of Relapse Management.
COVID-19 can trigger a relapsing form of hair loss, requiring long-term treatment strategies.
research Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.
Post-exposure syndromes are persistent conditions caused by past exposures, needing unique interventions.
research Intramuscular triamcinolone acetonide: An undervalued option for refractory alopecia areata
Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.
research Persistent hyperparathyroidism in vitamin D-dependent rickets type 2A does not prevent normalization of hypophosphatemia or healing of the rickets
Persistent hyperparathyroidism doesn't stop rickets healing or phosphate level normalization in VDDR2A.
research TELOGEN EFFLUVIUM: AN ETIOPATHOGENETIC THEORY
The paper suggests that telogen effluvium, a type of hair loss, may be a long-lasting condition triggered by stress or illness in people whose hair growth is unusually synchronized.
research Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
research TELOGEN EFFLUVIUM: A LATE COMPLICATION OF INFLUENZA A Sw H1N1 PNEUMONIA
Hair loss can happen after severe H1N1 flu but usually grows back in 4 months.
research Occurrence and persistence of symptoms, diagnoses and prescriptions after community-diagnosed COVID-19: a matched cohort study using the OpenSAFELY platform
Long-COVID symptoms like fatigue, cognitive issues, and mobility problems can last 6-12 months but are less common after milder illness.
research Tofacitinib treatment in a severe pediatric alopecia areata: A case report and a literature review
Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
research Immediate and Delayed Complications of Dexamethasone Cyclophosphamide Pulse (DCP) Therapy
DCP therapy causes side effects like weakness, flushing, headaches, and taste changes, but less frequently causes hypertension and diabetes.
research Alopecia areata in 2 patients treated with dupilumab: New onset and worsening
Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.
research Acute diffuse and total alopecia: A new subtype of alopecia areata with a favorable prognosis
A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.
research Patient-Reported Flare Symptoms Following COVID-19 Vaccination in Systemic Lupus Erythematosus
COVID-19 vaccines are generally safe for people with lupus, though some may experience mild flare symptoms.
research Platelet GPIIb/IIIa (P1A1/2) polymorphism in SLE: clinical and laboratory association
An antibiotic called co-trimoxazole can effectively treat autoimmune diseases.
research Dermatologic Changes Associated With Interleukin 2 Administration
IL-2 treatment causes skin eruptions and other reversible side effects, and may play a role in psoriasis.
research Tofacitinib in the Recalcitrant Cases of Alopecia Areata: A Pilot Study
Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research IMMEDIATE HYPERSENSITIVITY TO PERMANENT HAIR COLOR: 7
Tazarotene gel is more effective for acne than tretinoin and works as well as adapalene.
research MON-407 The Double-Edged Sword of Methimazole: Managing Graves' Disease with a Twist
Methimazole can cause severe low platelet count in Graves' disease patients, so monitoring and alternative treatments are important.
research A diagnostic clue: New onset alopecia sparing white hairs
Intralesional corticosteroids effectively treat localized alopecia areata, often sparing white hairs.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research Modification of the immune system with hydrogen sulfide and cyclosporine A
Age-related immune changes significantly affect disease development in other systems.